# Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in Psoriasis

> **NCT01826201** · PHASE2 · COMPLETED · sponsor: **Moleculin, LLC** · enrollment: 21 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** MOL4239
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01826201
- **Lead sponsor:** Moleculin, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2014-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01826201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01826201, "Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in Psoriasis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01826201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*